Department of Cardiothoracic Surgery, Jena University Hospital - Friedrich Schiller University Jena, Germany.
J Mol Cell Cardiol. 2012 Jan;52(1):125-35. doi: 10.1016/j.yjmcc.2011.10.022. Epub 2011 Nov 6.
Pressure overload induced heart failure affects cardiac mitochondrial function and leads to decreased respiratory capacity during contractile dysfunction. A similar cardiac mitochondrial dysfunction has been demonstrated by studies which induce heart failure through myocardial infarction or pacing. These heart failure models differ in their loading conditions to the heart and show nevertheless the same cardiac mitochondrial changes. Based on these observations we speculated that a workload independent mechanism may be responsible for the impairment in mitochondrial function after pressure overload, which may then also affect the skeletal muscle. We aimed to characterize changes in mitochondrial function of skeletal muscle during the transition from pressure overload (PO) induced cardiac hypertrophy to chronic heart failure. PO by transverse aortic constriction caused compensated hypertrophy at 2 weeks, HF with normal ejection fraction (EF) at 6 and 10 weeks, and hypertrophy with reduced EF at 20 weeks. Cardiac output was normal at all investigated time points. PO did not cause skeletal muscle atrophy. Mitochondrial respiratory capacity in soleus and gastrocnemius muscles showed an early increase (up to 6 weeks) and a later decline (significant at 20 weeks). Respiratory chain complex activities responded to PO in a biphasic manner. At 2 weeks, activity of complexes I and II was increased. These changes pseudo-normalized within the 6-10 week interval. At 20 weeks, all complexes showed reduced activities which coincided with clinical heart failure symptoms. However, both protein expression and supercomplex assembly (Blue-Native gel) remained normal. There were also no relevant changes in mRNA expression of genes involved in mitochondrial biogenesis. This temporal analysis reveals that mitochondrial function of skeletal muscle is changed early in the development of pressure overload induced heart failure without being directly influenced by an increased loading condition. The observed early increase and the later decline in respiratory capacity can be explained by concomitant activity changes of complex I and complex II and is not due to differences in gene expression or supercomplex assembly.
压力超负荷诱导的心力衰竭影响心脏线粒体功能,并导致收缩功能障碍期间呼吸能力下降。通过心肌梗死或起搏诱导心力衰竭的研究已经证明了类似的心脏线粒体功能障碍。这些心力衰竭模型在心脏的加载条件上有所不同,但显示出相同的心脏线粒体变化。基于这些观察,我们推测,在压力超负荷后,可能有一种与工作量无关的机制负责损害线粒体功能,这可能也会影响骨骼肌。我们旨在描述从压力超负荷(PO)诱导的心脏肥大到慢性心力衰竭过渡期间骨骼肌中线粒体功能的变化。通过横主动脉缩窄引起的 PO 导致 2 周时的代偿性肥大,6 和 10 周时的射血分数正常的心力衰竭(HF),以及 20 周时的 EF 降低的肥大。所有研究时间点的心输出量均正常。PO 不会导致骨骼肌萎缩。比目鱼肌和腓肠肌的线粒体呼吸能力早期增加(最多 6 周),随后下降(20 周时显著)。呼吸链复合物活性以双相方式对 PO 做出反应。在 2 周时,复合物 I 和 II 的活性增加。这些变化在 6-10 周的间隔内伪正常化。在 20 周时,所有复合物的活性均降低,这与临床心力衰竭症状相符。然而,蛋白质表达和超复合物组装(蓝 Native 凝胶)仍保持正常。涉及线粒体生物发生的基因的 mRNA 表达也没有相关变化。这种时间分析表明,骨骼肌线粒体功能在压力超负荷诱导的心力衰竭发展的早期就发生了变化,而不受加载条件增加的直接影响。观察到的呼吸能力的早期增加和随后的下降可以通过复合物 I 和复合物 II 的同时活性变化来解释,而不是由于基因表达或超复合物组装的差异。